Navigation Links
InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
Date:5/20/2009

InVitria’s BioProcess Theater presentation, “New Strategies for Optimizing CHO Performance,” to feature new supplement for CHO cell culture optimization called ZAP-CHO during BIO 2009 International Convention in Atlanta, GA. 

Fort Collins, CO May 19, 2009 / b3c newswire / – InVitria’s Director of Cell Culture, Dr. Steve Pettit, will present the performance enhancing features of ZAP-CHO, a new media component for Chinese hamster ovary (CHO) cell culture, at 3:30 pm on Wednesday, May 20, 2009 as part of BioProcess International’s BioProcess Theatre, a venue employed to facilitate the sharing of advances and discoveries in the biopharmaceutical sector.  

ZAP-CHO, a new product from InVitria, enhances performance of mammalian cell culture including improved cell growth and antibody production. It achieves these performance advantages in chemically defined media that are completely free of animal components. Previously, the performance seen with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum), BSA (bovine serum albumin) or plasma-derived HSA (human serum albumin) in cell culture media.

“Our team of scientists has developed supplements that not only meet the regulatory requirements of researchers using hybridoma and CHO cell culture, but it exceeds their performance expectations as well,” said Dr. Pettit. “InVitria products have been utilized by customers to successfully achieve greater cell productivity and growth; faster cell doublings; and improved consistency.”

InVitria’s other leading cell culture media supplements will also be part of the BIO Process Product Zone exhibition in Booth #5120 within the BIO 2009 International Convention from May 19-21.  These supplements include:
* Albumin-DX—whether you have problems with non-specific binding, biomarker stability, consistency or regulatory requirements, Albumin-DX was designed to answer the most difficult assay challenges.
* Cellastim—Cellastim outperforms plasma-derived albumin, bovine serum albumin and other sources of recombinant albumin.
* Lacromin—Lacromin is a CHO growth-factor that outperforms insulin and IGF-1.


About InVitria - www.InVitria.com

InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

Contact
Erik H. Vogel
InVitria
Marketing Manager
Phone: 1-800-916-8311
info@InVitria.com
www.InVitria.com


'/>"/>
b3c newswire

Related biology news :

1. InVitria Announces Launch of Recombinant Albumin for Diagnostics
2. Unveiling the structure of microcrystals
3. EC unveils new EU maritime policy
4. Scientists unveil structure of molecular target of many drugs
5. Tumor genome analysis unveils new insights into lung cancer
6. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
7. Research unveils new hope for deadly childhood disease
8. LTER unveils a new decadal science plan
9. Pixelplus Unveils Its PM1002 as A Practical Biometric Solution for Iris, Facial and Fingerprint Recognition
10. Unveiling the underwater ways of the white shark
11. Washington University unveils draft sequence of corn genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology: